Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Durvalumab patent expiry 2023 uk?

See the DrugPatentWatch profile for Durvalumab

When does durvalumab’s main patent protection expire in the UK (and does it line up with 2023)?

I don’t have enough provided information to state a specific “durvalumab patent expiry 2023” date for the UK. Patent expiry dates depend on the exact UK patent(s) covering durvalumab and their individual filing/term status, and they often differ from the date a product launches, the date a marketing authorisation is granted, or any “exclusivity” period.

If you share the specific patent number(s) you’re looking at (or a link to the UK patent register entry), I can help interpret the expected expiry and what “2023” would correspond to.

Is 2023 about patent expiry, regulatory exclusivity, or both?

In the UK, “loss of exclusivity” can refer to more than one thing:
- patent expiry (the legal protection for specific inventions/claims), and/or
- regulatory exclusivity (a protection period tied to marketing authorisation data/market exclusivity rules).

Without the underlying reference you’re using for “2023,” I can’t tell whether it refers to patents expiring in 2023, an exclusivity window ending, or a change in the ability to launch a biosimilar/competing product.

Can a biosimilar launch in the UK right after patent expiry?

Even if a patent expires, biosimilar entry can still be delayed by:
- other still-active patents covering related aspects (formulation, dosing regimens, manufacturing, etc.),
- litigation or injunctions, and
- regulatory/legal requirements for biosimilar development and approval.

So the “earliest possible” UK entry date for a biosimilar depends on the full set of active UK rights, not one single expiry year.

What details should you check to confirm “durvalumab patent expiry 2023 UK”?

To verify the exact UK situation, you typically need:
- the UK patent number(s) tied to durvalumab,
- the priority date(s) used to compute term,
- any patent term extensions (if applicable),
- whether any other related patents remain in force,
- whether “exclusivity” (regulatory) is being referenced instead of patents.

If you paste the patent numbers or the text/source where you saw “2023,” I can translate it into a clear expiry explanation for the UK.

Sources

No sources were provided in the prompt, so I didn’t cite any.



Other Questions About Durvalumab :

durvalumab loss of exclusivity durvalumab biosimilar durvalumab 500 mg price Durvalumab patent dauer? Durvalumab patent? When does the patent for durvalumab expire uk? Durvalumab loss of patent?